var data={"title":"Treatment protocols for esophagogastric cancer","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment protocols for esophagogastric cancer</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-esophagogastric-cancer/contributors\" class=\"contributor contributor_credentials\">Tim Brenner, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-esophagogastric-cancer/contributors\" class=\"contributor contributor_credentials\">Shrina Duggal, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-esophagogastric-cancer/contributors\" class=\"contributor contributor_credentials\">Jim Natale, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-esophagogastric-cancer/contributors\" class=\"contributor contributor_credentials\">Scott M Wirth, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-esophagogastric-cancer/contributors\" class=\"contributor contributor_credentials\">John W Mucenski, PharmD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-esophagogastric-cancer/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-esophagogastric-cancer/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 21, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H15190182\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with esophageal and gastric cancer, both in the <span class=\"nowrap\">adjuvant/neoadjuvant</span> setting and for advanced disease. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with esophagogastric cancer. Additional regimens may be added over time, particularly as treatment for esophagogastric cancer evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with esophagogastric cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=radiation-therapy-chemoradiotherapy-neoadjuvant-approaches-and-postoperative-adjuvant-therapy-for-localized-cancers-of-the-esophagus\" class=\"medical medical_review\">&quot;Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=adjuvant-and-neoadjuvant-treatment-of-gastric-cancer\" class=\"medical medical_review\">&quot;Adjuvant and neoadjuvant treatment of gastric cancer&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=systemic-therapy-for-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer\" class=\"medical medical_review\">&quot;Systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer&quot;</a>.)</p><p/><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class=\"headingAnchor\" id=\"H15190339\"><span class=\"h1\">REGIMENS</span></p><p class=\"headingAnchor\" id=\"H15196435\"><span class=\"h2\">Chemotherapy alone</span></p><p class=\"headingAnchor\" id=\"H4277333127\"><span class=\"h3\">Adjuvant capecitabine plus oxaliplatin (CAPOX) for stage II to III gastric cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F114120\" class=\"graphic graphic_table graphicRef114120 \">table 1</a>)</p><p class=\"headingAnchor\" id=\"H933416664\"><span class=\"h3\">Docetaxel, cisplatin, and fluorouracil (DCF)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F73324\" class=\"graphic graphic_table graphicRef73324 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H15190442\"><span class=\"h3\">Modified docetaxel, cisplatin, and fluorouracil (modified DCF)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F79612\" class=\"graphic graphic_table graphicRef79612 \">table 3</a>)</p><p class=\"headingAnchor\" id=\"H933416689\"><span class=\"h3\">Epirubicin, cisplatin, and fluorouracil (ECF)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F62502\" class=\"graphic graphic_table graphicRef62502 \">table 4</a>)</p><p class=\"headingAnchor\" id=\"H933416714\"><span class=\"h3\">Epirubicin, cisplatin, and capecitabine (ECX)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F53899\" class=\"graphic graphic_table graphicRef53899 \">table 5</a>)</p><p class=\"headingAnchor\" id=\"H933416739\"><span class=\"h3\">Epirubicin, oxaliplatin, and capecitabine (EOX)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F75288\" class=\"graphic graphic_table graphicRef75288 \">table 6</a>)</p><p class=\"headingAnchor\" id=\"H933416764\"><span class=\"h3\">FOLFIRI (fluorouracil plus leucovorin and irinotecan)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the published experience in advanced esophagogastric cancer is with slightly different regimens, most clinicians use the same FOLFIRI regimen as is used for advanced colorectal cancer (<a href=\"image.htm?imageKey=ONC%2F76300\" class=\"graphic graphic_table graphicRef76300 \">table 7</a>). (See <a href=\"topic.htm?path=systemic-therapy-for-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer#H225803592\" class=\"medical medical_review\">&quot;Systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer&quot;, section on 'Irinotecan-containing regimens'</a>.)</p><p class=\"headingAnchor\" id=\"H933416821\"><span class=\"h3\">Irinotecan plus cisplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F62115\" class=\"graphic graphic_table graphicRef62115 \">table 8</a>)</p><p class=\"headingAnchor\" id=\"H933416793\"><span class=\"h3\">Modified FOLFOX6 and modified FOLFOX7 (fluorouracil plus leucovorin and oxaliplatin)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the published experience in advanced esophagogastric cancer is with slightly different regimens, most clinicians use the same modified FOLFOX6 and FOLFOX7 regimens as are used for colorectal cancer (<a href=\"image.htm?imageKey=ONC%2F50132\" class=\"graphic graphic_table graphicRef50132 \">table 9</a> and <a href=\"image.htm?imageKey=ONC%2F55829\" class=\"graphic graphic_table graphicRef55829 \">table 10</a>). (See <a href=\"topic.htm?path=systemic-therapy-for-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer#H524986292\" class=\"medical medical_review\">&quot;Systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer&quot;, section on 'Oxaliplatin combinations'</a>.)</p><p class=\"headingAnchor\" id=\"H521825484\"><span class=\"h3\">Capecitabine plus oxaliplatin advanced esophagogastric cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F112347\" class=\"graphic graphic_table graphicRef112347 \">table 11</a>)</p><p class=\"headingAnchor\" id=\"H958003\"><span class=\"h3\">Trastuzumab-containing regimens for HER2-positive advanced adenocarcinomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(See <a href=\"topic.htm?path=systemic-therapy-for-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer#H33\" class=\"medical medical_review\">&quot;Systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer&quot;, section on 'HER2-overexpressing adenocarcinomas'</a>.)</p><p class=\"headingAnchor\" id=\"H1121265809\"><span class=\"h4\">Trastuzumab plus capecitabine and cisplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F86570\" class=\"graphic graphic_table graphicRef86570 \">table 12</a>)</p><p class=\"headingAnchor\" id=\"H1347756028\"><span class=\"h4\">Trastuzumab plus fluorouracil and cisplatin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F86571\" class=\"graphic graphic_table graphicRef86571 \">table 13</a>)</p><p class=\"headingAnchor\" id=\"H708996723\"><span class=\"h4\">FOLFOX plus trastuzumab chemotherapy for HER2-overexpressing metastatic gastric and gastroesophageal junction cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F109416\" class=\"graphic graphic_table graphicRef109416 \">table 14</a>)</p><p class=\"headingAnchor\" id=\"H604694817\"><span class=\"h4\">Capecitabine and oxaliplatin (CAPOX) plus trastuzumab for HER2-overexpressing advanced gastric and gastroesophageal junction cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F109415\" class=\"graphic graphic_table graphicRef109415 \">table 15</a>)</p><p class=\"headingAnchor\" id=\"H15196507\"><span class=\"h2\">Concurrent chemoradiotherapy</span></p><p class=\"headingAnchor\" id=\"H933416871\"><span class=\"h3\">Weekly carboplatin plus paclitaxel with concurrent radiotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F68266\" class=\"graphic graphic_table graphicRef68266 \">table 16</a>)</p><p class=\"headingAnchor\" id=\"H20092197\"><span class=\"h3\">Trimodality therapy with cisplatin plus fluorouracil and concurrent radiotherapy followed by surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F87313\" class=\"graphic graphic_table graphicRef87313 \">table 17</a>)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 85680 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H15190182\" id=\"outline-link-H15190182\">INTRODUCTION</a></li><li><a href=\"#H15190339\" id=\"outline-link-H15190339\">REGIMENS</a><ul><li><a href=\"#H15196435\" id=\"outline-link-H15196435\">Chemotherapy alone</a><ul><li><a href=\"#H4277333127\" id=\"outline-link-H4277333127\">- Adjuvant capecitabine plus oxaliplatin (CAPOX) for stage II to III gastric cancer</a></li><li><a href=\"#H933416664\" id=\"outline-link-H933416664\">- Docetaxel, cisplatin, and fluorouracil (DCF)</a></li><li><a href=\"#H15190442\" id=\"outline-link-H15190442\">- Modified docetaxel, cisplatin, and fluorouracil (modified DCF)</a></li><li><a href=\"#H933416689\" id=\"outline-link-H933416689\">- Epirubicin, cisplatin, and fluorouracil (ECF)</a></li><li><a href=\"#H933416714\" id=\"outline-link-H933416714\">- Epirubicin, cisplatin, and capecitabine (ECX)</a></li><li><a href=\"#H933416739\" id=\"outline-link-H933416739\">- Epirubicin, oxaliplatin, and capecitabine (EOX)</a></li><li><a href=\"#H933416764\" id=\"outline-link-H933416764\">- FOLFIRI (fluorouracil plus leucovorin and irinotecan)</a></li><li><a href=\"#H933416821\" id=\"outline-link-H933416821\">- Irinotecan plus cisplatin</a></li><li><a href=\"#H933416793\" id=\"outline-link-H933416793\">- Modified FOLFOX6 and modified FOLFOX7 (fluorouracil plus leucovorin and oxaliplatin)</a></li><li><a href=\"#H521825484\" id=\"outline-link-H521825484\">- Capecitabine plus oxaliplatin advanced esophagogastric cancer</a></li><li><a href=\"#H958003\" id=\"outline-link-H958003\">- Trastuzumab-containing regimens for HER2-positive advanced adenocarcinomas</a><ul><li><a href=\"#H1121265809\" id=\"outline-link-H1121265809\">Trastuzumab plus capecitabine and cisplatin</a></li><li><a href=\"#H1347756028\" id=\"outline-link-H1347756028\">Trastuzumab plus fluorouracil and cisplatin</a></li><li><a href=\"#H708996723\" id=\"outline-link-H708996723\">FOLFOX plus trastuzumab chemotherapy for HER2-overexpressing metastatic gastric and gastroesophageal junction cancer</a></li><li><a href=\"#H604694817\" id=\"outline-link-H604694817\">Capecitabine and oxaliplatin (CAPOX) plus trastuzumab for HER2-overexpressing advanced gastric and gastroesophageal junction cancer</a></li></ul></li></ul></li><li><a href=\"#H15196507\" id=\"outline-link-H15196507\">Concurrent chemoradiotherapy</a><ul><li><a href=\"#H933416871\" id=\"outline-link-H933416871\">- Weekly carboplatin plus paclitaxel with concurrent radiotherapy</a></li><li><a href=\"#H20092197\" id=\"outline-link-H20092197\">- Trimodality therapy with cisplatin plus fluorouracil and concurrent radiotherapy followed by surgery</a></li></ul></li></ul></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/85680|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/114120\" class=\"graphic graphic_table\">- Adjuvant CAPOX chemotherapy for stage II to III gastric cancer</a></li><li><a href=\"image.htm?imageKey=ONC/73324\" class=\"graphic graphic_table\">- DCF for advanced gastric cancer</a></li><li><a href=\"image.htm?imageKey=ONC/79612\" class=\"graphic graphic_table\">- Modified DCF for advanced gastric cancer</a></li><li><a href=\"image.htm?imageKey=ONC/62502\" class=\"graphic graphic_table\">- ECF for advanced esophagogastric cancer</a></li><li><a href=\"image.htm?imageKey=ONC/53899\" class=\"graphic graphic_table\">- ECX for advanced esophagogastric cancer</a></li><li><a href=\"image.htm?imageKey=ONC/75288\" class=\"graphic graphic_table\">- EOX for advanced esophagogastric cancer</a></li><li><a href=\"image.htm?imageKey=ONC/76300\" class=\"graphic graphic_table\">- FOLFIRI regimen</a></li><li><a href=\"image.htm?imageKey=ONC/62115\" class=\"graphic graphic_table\">- Irinotecan plus cisplatin for advanced gastric cancer</a></li><li><a href=\"image.htm?imageKey=ONC/50132\" class=\"graphic graphic_table\">- Modified FOLFOX6</a></li><li><a href=\"image.htm?imageKey=ONC/55829\" class=\"graphic graphic_table\">- Modified FOLFOX7 regimen</a></li><li><a href=\"image.htm?imageKey=ONC/112347\" class=\"graphic graphic_table\">- Capecitabine plus oxaliplatin advanced esophagogastric cancer</a></li><li><a href=\"image.htm?imageKey=ONC/86570\" class=\"graphic graphic_table\">- Trastuzumab plus cape and cis HER2 adv EG cancers</a></li><li><a href=\"image.htm?imageKey=ONC/86571\" class=\"graphic graphic_table\">- Trastuzumab plus FU and cis HER2 adv EG cancers</a></li><li><a href=\"image.htm?imageKey=ONC/109416\" class=\"graphic graphic_table\">- FOLFOX plus trastuzumab for metastatic gastric and GEJ cancer</a></li><li><a href=\"image.htm?imageKey=ONC/109415\" class=\"graphic graphic_table\">- CAPOX plus trastuzumab for advanced gastric and GEJ cancer</a></li><li><a href=\"image.htm?imageKey=ONC/68266\" class=\"graphic graphic_table\">- Carboplatin and paclitaxel with RT for EGJ cancer</a></li><li><a href=\"image.htm?imageKey=ONC/87313\" class=\"graphic graphic_table\">- Cisplatin FU RT for EGJ cancer</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-and-neoadjuvant-treatment-of-gastric-cancer\" class=\"medical medical_review\">Adjuvant and neoadjuvant treatment of gastric cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=radiation-therapy-chemoradiotherapy-neoadjuvant-approaches-and-postoperative-adjuvant-therapy-for-localized-cancers-of-the-esophagus\" class=\"medical medical_review\">Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-therapy-for-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer\" class=\"medical medical_review\">Systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer</a></li></ul></div></div>","javascript":null}